Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT07488884 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer Resectable
Pancreatic Cancer

Interventions

DRUG: Nogapendekin Alfa Inbakicept (N803)
DRUG: Sotevtamab
DRUG: Zabadinostat (CXD101)
DRUG: Nab paclitaxel / gemcitabine

Sponsor

ImmunityBio, Inc.